Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

Helen F. Graham Cancer Center
& Research Institute

Prostate Cancer

Nearly one in six American men will be diagnosed with prostate cancer. While most men with prostate cancer have no symptoms, prostate cancer can be found during a regular checkup using a combination of a blood test called a PSA and a digital rectal exam. Even better news, the number of Delaware men being screened early and diagnosed at the most treatable stage is going up.

The American Cancer Society recommends that all men 50 and older talk with their doctors to make an informed decision about whether to be screened for prostate cancer. If you are at higher risk, have that discussion earlier:

  • By age 40 if you have more than one first-degree relative (father, brother or son) who had prostate cancer before age 65.
  • By age 45 if you have one first-degree relative (father, brother or son) who had prostate cancer before age 65.

To learn more, call 302-623-4661 or visit the American Cancer Society.

Click here to Find a Doctor or call us at 800-693-CARE.

Screening for Life and Health Care Connection

Don’t let lack of insurance or copays keep you from getting screened! Screening for Life and the Health Care Connection Screening for Life provides payment for cancer screening tests recommended by your doctor if you meet age, income and insurance guidelines. This program is a cooperative effort of the Delaware Division of Public Health and the U.S. Centers for Disease Control and Prevention (CDC). The Health Care Connection simplifies the eligibility screening process to help uninsured Delawareans access primary care and medical specialists, disease prevention services — such as cancer screenings — and helps ensure access to prescription programs, laboratory and radiology services.

To learn more, call 302-623-4661 or visit Screening For Life or the Health Care Connection & Voluntary Initiative Program.

Community Health Outreach and Education Program
Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Newark, DE 19713 directions
302-623-4661